CN1674912A - 治疗男性勃起障碍的方法 - Google Patents

治疗男性勃起障碍的方法 Download PDF

Info

Publication number
CN1674912A
CN1674912A CNA038186934A CN03818693A CN1674912A CN 1674912 A CN1674912 A CN 1674912A CN A038186934 A CNA038186934 A CN A038186934A CN 03818693 A CN03818693 A CN 03818693A CN 1674912 A CN1674912 A CN 1674912A
Authority
CN
China
Prior art keywords
compositions
patient
prostaglandin
described method
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038186934A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·L·亚格
那迪·布亚迪金
瑟维特·布亚迪金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexmed Holdings Inc
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/236,485 external-priority patent/US7105571B2/en
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of CN1674912A publication Critical patent/CN1674912A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA038186934A 2002-09-06 2003-09-05 治疗男性勃起障碍的方法 Pending CN1674912A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/236,485 US7105571B2 (en) 2000-01-10 2002-09-06 Prostaglandin compositions and methods of treatment for male erectile dysfunction
US10/236,485 2002-09-06
US48327803P 2003-06-27 2003-06-27
US60/483,278 2003-06-27

Publications (1)

Publication Number Publication Date
CN1674912A true CN1674912A (zh) 2005-09-28

Family

ID=31980977

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038186934A Pending CN1674912A (zh) 2002-09-06 2003-09-05 治疗男性勃起障碍的方法

Country Status (10)

Country Link
EP (1) EP1534297A1 (fr)
JP (1) JP2006512291A (fr)
KR (1) KR20050057245A (fr)
CN (1) CN1674912A (fr)
AU (1) AU2003273291A1 (fr)
CA (1) CA2493723A1 (fr)
EA (1) EA200500452A1 (fr)
IL (1) IL166273A0 (fr)
NO (1) NO20050658L (fr)
WO (1) WO2004022064A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
JP2006520788A (ja) * 2003-03-21 2006-09-14 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物による血管形成促進および方法
MXPA05010069A (es) * 2003-03-21 2005-11-23 Nexmed Holdings Inc Composiciones de prostaglandina para el tratamiento de la disfuncion erectil.
EP3266458A1 (fr) 2016-07-05 2018-01-10 Fagron B.V. Procédé et composition et kit pour traiter un dysfonctionnement érectile

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
WO2003070281A1 (fr) * 2002-02-15 2003-08-28 Nexmed (Holdings), Inc. Composition de prostaglandine pour le traitement des troubles de l'erection

Also Published As

Publication number Publication date
JP2006512291A (ja) 2006-04-13
EP1534297A1 (fr) 2005-06-01
NO20050658L (no) 2005-04-01
EA200500452A1 (ru) 2005-10-27
AU2003273291A1 (en) 2004-03-29
CA2493723A1 (fr) 2004-03-18
WO2004022064A1 (fr) 2004-03-18
IL166273A0 (en) 2006-01-15
KR20050057245A (ko) 2005-06-16

Similar Documents

Publication Publication Date Title
CN1551784A (zh) 前列腺素组合物和治疗男性勃起功能障碍的方法
CN1206998C (zh) 治疗阴茎勃起障碍的组合物和方法
CN1173700C (zh) 改善女性性功能障碍的组合物和方法
CN1394140A (zh) 前列腺素组合物和治疗男性勃起机能障碍的方法
CN1761461A (zh) 治疗早泄的组合物和方法
CN1607950A (zh) 用于口腔施用的包含烟碱的液体药物制剂
CN1610559A (zh) 用于治疗勃起障碍的前列腺组合物
CN1665485A (zh) 改善人类女性性功能障碍的组合物及方法
US8632813B2 (en) Prostaglandin compositions and methods for the treatment of vasospasm
CN1674912A (zh) 治疗男性勃起障碍的方法
CN1771041A (zh) 治疗勃起功能障碍的前列腺素组合物
CN1774237A (zh) 前列腺素组合物及其促进血管生成的方法
TW200407149A (en) Methods of treatment of male erectile dysfunction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication